Latest Europe News

Nufarm Limited reported a $165.3 million statutory loss for FY25, driven by restructuring costs in Seed Technologies despite strong Crop Protection growth. A CEO transition and refinancing moves set the stage for FY26.

Biotron Limited has launched a $1.5 million non-renounceable rights issue to fund its strategic acquisition of Sedarex Limited and support ongoing drug development programs. The capital raise follows shareholder approval and aims to diversify Biotron’s portfolio with a next-generation general anaesthetic.

Clover Corporation Limited reported a standout FY25 with robust revenue growth and a sharp rise in profitability, underpinned by strategic market expansion and product innovation. The company’s strengthened balance sheet and optimistic FY26 outlook signal continued momentum.

Clover Corporation delivered a robust FY25 with strong second-half sales and operational milestones, positioning itself for continued growth in FY26 amid ongoing innovation and market expansion.

Viridis Mining and Minerals has received a significant US$100 million Letter of Interest from Export Development Canada, reinforcing the financing framework for its Colossus Rare Earths Project in Brazil. This follows prior support from French and Brazilian export credit agencies, positioning the company for a Final Investment Decision in 2026.

Linius Technologies has secured a 12-month extension with Racing.com and reported ahead-of-schedule progress on its AI-powered proof of concept with a top European soccer league, signaling growth in sports media technology.

James Hardie Industries has appointed Nigel Stein as the new Chair of its Board and established an Integration and Performance Committee to oversee the AZEK acquisition integration and enhance shareholder engagement.

James Hardie Industries reports a 34% jump in Q2 FY26 net sales driven by the AZEK acquisition and European growth, while grappling with margin pressures and integration costs.

Paradigm Biopharmaceuticals has drawn down US$5 million under its convertible note facility to fund the accelerated expansion of its global Phase 3 trial for knee osteoarthritis treatment.

Argent BioPharma has locked in an A$11 million convertible financing facility to finalize its strategic acquisition of AusCann assets and accelerate its growth plans, including a potential US stock exchange listing.

Adisyn Ltd has successfully validated a critical pre-clean sub-process in its proprietary low-temperature graphene deposition method, marking a significant technical milestone toward revolutionizing semiconductor interconnects.

Bioxyne Limited is expanding its footprint with a new UK GMP-certified medicinal cannabis manufacturing site, backed by £850,000 in funding from South of Scotland Enterprise. This move positions the company to tap into the UK’s growing medicinal cannabis market, the second largest in Europe.